logo-loader
viewSummit Therapeutics PLC

Summit Therapeutics collects $1mln payment as Latin American patients enrolled

“We’re pleased with the progress we have made in enrolling our Phase 3 clinical trials, and we look forward to the results of the trials expected in the second half of 2021”

Summit Therapeutics PLC -

Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT) has received a US$1mln milestone payment after enrolling initial patients at trial sites in Latin America as part of phase-III clinical trials of its ridinilazole treatment for C. difficile infection.

The payment is the first under its license and collaboration agreement with Eurofarma Laboratórios SA, under which it is entitled to receive a further US$2.75mln upon the achievement of additional staged patient enrolment targets in Latin America, along with other development and commercial milestones.

READ: Summit Therapeutics gets US$50mln backing from biotech billionaire Bob Duggan

“We’re pleased with the progress we have made in enrolling our Phase 3 clinical trials, and we look forward to the results of the trials expected in the second half of 2021,” said chairman and chief executive Glyn Edwards.

Summit, which is also funding the trials with US government funds, showed in Phase 2 trials that the drug could kill C.diff infections while preserving healthy microorganisms in the gastrointestinal tract. 

The firm’s Ri-CoDIFy phase III clinical trial assessment, which began in last February, is pitting next-generation antibiotic ridinilazole against vancomycin, the current standard of care.

Quick facts: Summit Therapeutics PLC

Price: - -

AIM:SUMM
Market: AIM
Market Cap: -
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics' Glyn Edwards talks US$50mln backing and ridinilazole...

Summit Therapeutics PLC's (LON:SUMM, NASDAQ:SMMT) CEO Glyn Edwards sat down with Proactive London's Andrew Scott following the news of a US$50mln funding deal with biotech billionaire Bob Duggan. The investment will help get the company’s next-generation antibiotic through phase III clinical...

on 9/12/19

2 min read